JP2010536373A - 疾患を診断するための方法および組成物 - Google Patents

疾患を診断するための方法および組成物 Download PDF

Info

Publication number
JP2010536373A
JP2010536373A JP2010521896A JP2010521896A JP2010536373A JP 2010536373 A JP2010536373 A JP 2010536373A JP 2010521896 A JP2010521896 A JP 2010521896A JP 2010521896 A JP2010521896 A JP 2010521896A JP 2010536373 A JP2010536373 A JP 2010536373A
Authority
JP
Japan
Prior art keywords
transcription factor
promoter
ligand
polynucleotide
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010521896A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010536373A5 (https=
Inventor
ロバート ピー． ビーチ
トーマス ディー． リード
ロバート パッツィヒ
Original Assignee
イントレキソン コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イントレキソン コーポレーション filed Critical イントレキソン コーポレーション
Publication of JP2010536373A publication Critical patent/JP2010536373A/ja
Publication of JP2010536373A5 publication Critical patent/JP2010536373A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/66—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2010521896A 2007-08-23 2008-08-25 疾患を診断するための方法および組成物 Withdrawn JP2010536373A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US95747407P 2007-08-23 2007-08-23
US1465407P 2007-12-18 2007-12-18
US4794008P 2008-04-25 2008-04-25
PCT/US2008/010040 WO2009025866A1 (en) 2007-08-23 2008-08-25 Methods and compositions for diagnosing disease

Publications (2)

Publication Number Publication Date
JP2010536373A true JP2010536373A (ja) 2010-12-02
JP2010536373A5 JP2010536373A5 (https=) 2011-10-13

Family

ID=40378488

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010521896A Withdrawn JP2010536373A (ja) 2007-08-23 2008-08-25 疾患を診断するための方法および組成物

Country Status (11)

Country Link
US (5) US20090098055A1 (https=)
EP (1) EP2185730A4 (https=)
JP (1) JP2010536373A (https=)
KR (1) KR20100049084A (https=)
CN (1) CN101835908A (https=)
AU (1) AU2008289461A1 (https=)
CA (1) CA2698212A1 (https=)
MX (1) MX2010001993A (https=)
NZ (1) NZ583430A (https=)
WO (1) WO2009025866A1 (https=)
ZA (1) ZA201000983B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2715078C (en) * 2007-09-26 2019-07-23 Intrexon Corporation Synthetic 5'utrs, expression vectors, and methods for increasing transgene expression
MX2010003371A (es) * 2007-09-28 2010-05-05 Intrexon Corp Constructos interruptores genicos terapeuticos y biorreactores para la expresion de moleculas bioterapeuticas y usos de los mismos.
RU2573912C2 (ru) 2008-10-08 2016-01-27 Интрексон Корпорейшн Сконструированные клетки, экспрессирующие множественные иммуномодуляторы, и их применения
CN103328500B (zh) * 2010-08-04 2018-01-26 西兹尔生物技术有限公司 用于癌症的诊断和治疗的方法和化合物
JP6189754B2 (ja) 2011-03-04 2017-08-30 イントレキソン コーポレーション タンパク質を条件的に発現するベクター
CN106187812A (zh) * 2011-09-08 2016-12-07 英特瑞克斯顿股份有限公司 结晶状二酰基肼及其用途
CN105510586B (zh) * 2015-12-22 2017-09-12 湖北鹊景生物医学有限公司 用于肺癌诊断的试剂盒及其使用方法
CN111848732B (zh) * 2019-04-30 2024-03-12 上海细胞治疗集团有限公司 多肽组合物及疫苗
CN111848733B (zh) * 2019-04-30 2024-03-12 上海细胞治疗集团有限公司 一种多肽组合物及疫苗
CN110051841B (zh) * 2019-05-28 2021-02-02 北京大学 Nat10抑制剂在制备用于抑制hif表达的药物中的应用
CN111304226A (zh) * 2019-11-21 2020-06-19 福州福瑞医学检验实验室有限公司 一种编码cyp1b1基因突变体的核酸及其应用
RU2728683C1 (ru) * 2019-12-03 2020-07-30 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кубанский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО КубГМУ Минздрава России) Способ ранней диагностики отторжения трансплантата
KR20230117327A (ko) * 2020-09-03 2023-08-08 어빈 에스.와이. 첸 가용성 알칼리성 포스파타제 작제물 및 가용성 알칼리성 포스파타제 작제물을 인코딩하는 폴리뉴클레오티드를 포함하는 발현 벡터
CN115770296B (zh) * 2022-07-15 2024-05-10 青岛大学 circEYA3在制备先天性心脏病诊断/治疗的产品中的应用
CA3262218A1 (en) 2022-07-19 2024-01-25 Rampart Bioscience, Inc. CIRCULAR NON-IMMUNOGENEOUS NON-VIRAL DNA VECTORS
WO2025090786A1 (en) * 2023-10-24 2025-05-01 Rampart Bioscience, Inc. Reduced immunogenic gene therapy protocols using circular, extended cruciform containing non-viral vectors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066613A2 (en) * 2001-02-20 2002-08-29 Rheogene Holdings, Inc Novel ecdysone receptor/invertebrate retinoid x receptor-based inducible gene expression system
JP2005507247A (ja) * 2001-09-26 2005-03-17 レオジーン・ホールディングス，インコーポレーテッド コナジラミエクジソン受容体核酸、ポリペプチド、およびそれらの使用
US20060228776A1 (en) * 2004-10-22 2006-10-12 Neurologix, Inc. PINK-1 promoter

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4409331A (en) 1979-03-28 1983-10-11 Damon Corporation Preparation of substances with encapsulated cells
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
CA1196862A (en) 1983-06-01 1985-11-19 Connaught Laboratories Limited Microencapsulation of living tissue and cells
US4806355A (en) 1983-06-06 1989-02-21 Connaught Laboratories Limited Microencapsulation of living tissue and cells
US4689293A (en) 1983-06-06 1987-08-25 Connaught Laboratories Limited Microencapsulation of living tissue and cells
US4680174A (en) 1984-05-24 1987-07-14 Damon Biotech, Inc. Induction of immune response by immunization with encapsulated antigen-producing cells
US4985461A (en) 1985-10-21 1991-01-15 Rohm And Haas Company Insecticidal N'-substituted-N,N'-diacylhydrazines
US5117057A (en) 1985-10-21 1992-05-26 Rohm And Haas Company Insecticidal N' substituted-N-N'-disubstituted-hydrazines
US5225443A (en) 1986-05-01 1993-07-06 Rohm And Haas Company Insecticidal N'-substituted-N'-substituted N,N'-diacylhydrazines
US5786216A (en) 1987-11-17 1998-07-28 Cytotherapeutics, Inc. Inner-supported, biocompatible cell capsules
US5773286A (en) 1987-11-17 1998-06-30 Cytotherapeutics, Inc. Inner supported biocompatible cell capsules
US4981784A (en) 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5529914A (en) 1990-10-15 1996-06-25 The Board Of Regents The Univeristy Of Texas System Gels for encapsulation of biological materials
IL100643A (en) 1991-01-25 1996-10-31 Nippon Kayaku Kk History of hydrazine and pesticides containing these histories as an active ingredient
US5800829A (en) 1991-04-25 1998-09-01 Brown University Research Foundation Methods for coextruding immunoisolatory implantable vehicles with a biocompatible jacket and a biocompatible matrix core
ATE156344T1 (de) 1991-04-25 1997-08-15 Univ Brown Res Found Implantierbare, biokompatible immunisolator- trägersubstanz zum abgeben ausgesuchter, therapeutischer produkte
EP0610441A4 (en) 1991-10-29 1996-01-10 Clover Cons Ltd CROSSLINKABLE POLYSACCHARIDES, POLYCATIONS AND LIPIDS CAN BE USED TO ENCODE AND DISPENSE MEDICINAL PRODUCTS.
US5545423A (en) 1991-11-25 1996-08-13 Vivorx, Inc. Cytoprotective, biocompatible, retrievable macrocapsule containment systems for biologically active materials
US5530028A (en) 1992-11-23 1996-06-25 Rohm And Haas Company Insecticidal N'-substituted-N,N'-diacylhydrazines
US6013836A (en) 1992-02-28 2000-01-11 Rohm And Haas Company Insecticidal N'-substituted-N,N'-disubstitutedhydrazines
US5573934A (en) 1992-04-20 1996-11-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
US5334640A (en) 1992-04-08 1994-08-02 Clover Consolidated, Ltd. Ionically covalently crosslinked and crosslinkable biocompatible encapsulation compositions and methods
US5286495A (en) 1992-05-11 1994-02-15 University Of Florida Process for microencapsulating cells
DK0746582T3 (da) 1993-04-27 2000-08-21 Cytotherapeutics Inc Membran dannet af en acrylonitril-baseret polymer
NZ269041A (en) 1993-06-23 1998-02-26 Univ Brown Res Found Implantable encapsulation device having a cell-tight dry seal at an opening thereof
US5908623A (en) 1993-08-12 1999-06-01 Cytotherapeutics, Inc. Compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
SG48813A1 (en) 1993-08-12 1998-05-18 Cytotherapeutics Inc Improved composition and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
US5858350A (en) 1993-12-01 1999-01-12 Marine Polymer Technologies Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system
FR2714830B1 (fr) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
DK1666585T3 (da) 1994-01-13 2009-01-12 Rogosin Inst Makroindkapslede sekretoriske celler
USRE39542E1 (en) 1994-01-13 2007-04-03 The Rogosin Institute Preparation of agarose coated, solid agarose-collagen beads containing secretory cells
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
US5651980A (en) 1994-04-15 1997-07-29 Biohybrid Technologies, Inc. Methods of use of uncoated gel particles
US6306454B1 (en) 1994-10-17 2001-10-23 Baxter International Inc. Method for producing improved medical devices and devices so produced
FR2727679B1 (fr) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
US6281015B1 (en) 1994-12-16 2001-08-28 Children's Medical Center Corp. Localized delivery of factors enhancing survival of transplanted cells
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
US5916790A (en) 1995-03-03 1999-06-29 Metabolex, Inc. Encapsulation compositions, and methods
US6126936A (en) 1995-03-10 2000-10-03 Biohybrid Technologies Llc Microcapsules and composite microreactors for immunoisolation of cells
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
WO1997010807A1 (en) 1995-09-22 1997-03-27 Gore Hybrid Technologies, Inc. Improved cell encapsulation device
US6224912B1 (en) 1996-04-03 2001-05-01 The Rogo Institute Cancer-cell proliferation-suppressing material produced by cancer cells restricted by entrapment
US6723531B2 (en) 1996-04-05 2004-04-20 The Salk Institute For Biological Studies Method for modulating expression of exogenous genes in mammalian systems, and products related thereto
US20040086494A1 (en) * 1996-10-07 2004-05-06 John Constance Mary Immune privileged cells for delivery of proteins and peptides
US6287558B1 (en) 1997-08-01 2001-09-11 Biohybrio Technologies Llc Devices containing cells or tissue and an agent that inhibits damage by a host cell molecule
US6368612B1 (en) 1997-12-12 2002-04-09 Biohybrid Technologies Llc Devices for cloaking transplanted cells
US6342596B1 (en) * 1998-05-05 2002-01-29 Hsf Pharmaceuticals S.A. Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress
US6333318B1 (en) 1998-05-14 2001-12-25 The Salk Institute For Biological Studies Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto
US6258603B1 (en) 1998-06-17 2001-07-10 Rohm And Haas Company Ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US6818018B1 (en) 1998-08-14 2004-11-16 Incept Llc In situ polymerizable hydrogels
US6495161B1 (en) 1999-03-09 2002-12-17 Vivorx, Inc. Cytoprotective biocompatible containment systems for biologically active materials and methods of making same
US6342896B1 (en) 1999-03-19 2002-01-29 Microsoft Corporation Methods and apparatus for efficiently implementing and modifying foreground and background color selections
US6365385B1 (en) 1999-03-22 2002-04-02 Duke University Methods of culturing and encapsulating pancreatic islet cells
US6303355B1 (en) 1999-03-22 2001-10-16 Duke University Method of culturing, cryopreserving and encapsulating pancreatic islet cells
US6558665B1 (en) 1999-05-18 2003-05-06 Arch Development Corporation Encapsulating particles with coatings that conform to size and shape of the particles
AU4940700A (en) * 1999-05-28 2000-12-18 Sangamo Biosciences, Inc. Gene switches
AU2001249315A1 (en) 2000-03-22 2001-10-03 Rheogene, Inc. Ecdysone receptor-based inducible gene expression system
US20040033600A1 (en) * 2001-03-21 2004-02-19 Palli Subba Reddy Ecdysone receptor-based inducible gene expression system
US6337008B1 (en) 2000-06-12 2002-01-08 Alcan International Limited Electrolysis cells
US8105825B2 (en) 2000-10-03 2012-01-31 Intrexon Corporation Multiple inducible gene regulation system
AU2002213143A1 (en) 2000-10-12 2002-04-22 Institute Of Materials Research And Engineering Non-disruptive three-dimensional culture and harvest system for anchorage-dependent cells
WO2002066614A2 (en) * 2001-02-20 2002-08-29 Rheogene Holdings, Inc. Chimeric retinoid x receptors and their use in a novel ecdysone receptor-based inducible gene expression system
EP1534738B1 (en) 2001-02-20 2012-06-20 Intrexon Corporation Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
EP1373470B1 (en) * 2001-02-20 2013-04-24 Intrexon Corporation Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
KR100453853B1 (ko) 2001-08-28 2004-10-20 삼성전자주식회사 저전압 불 휘발성 반도체 메모리 장치 및 그것의 독출 방법
US20040266708A1 (en) * 2002-01-29 2004-12-30 Paul Diamond Regulation of polynucleic acid activity and expression
US6727322B2 (en) 2002-04-01 2004-04-27 The University Of Akron Amphiphilic networks, implantable immunoisolatory devices, and methods of preparation
US20040005302A1 (en) 2002-04-30 2004-01-08 Gonzalo Hortelano Encapsulated cells to elicit immune responses
US7226978B2 (en) 2002-05-22 2007-06-05 Dexcom, Inc. Techniques to improve polyurethane membranes for implantable glucose sensors
US7375093B2 (en) 2002-07-05 2008-05-20 Intrexon Corporation Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US20080050808A1 (en) 2002-10-09 2008-02-28 Reed Thomas D DNA modular cloning vector plasmids and methods for their use
US7785871B2 (en) 2002-10-09 2010-08-31 Intrexon Corporation DNA cloning vector plasmids and methods for their use
US7304161B2 (en) 2003-02-10 2007-12-04 Intrexon Corporation Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex
US7304162B2 (en) * 2003-02-21 2007-12-04 Intrexon Corporation Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
WO2004076657A2 (en) * 2003-02-28 2004-09-10 Mcgill University Cell and enzyme compositions for modulating bile acids, cholesterol and triglycerides
US7456315B2 (en) * 2003-02-28 2008-11-25 Intrexon Corporation Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
WO2005013885A2 (en) * 2003-08-07 2005-02-17 Healor Ltd. Pharmaceutical compositions and methods for accelerating wound healing
US20070238675A1 (en) * 2003-08-11 2007-10-11 Phillips M I Stem Cell Beacon
SE526959C2 (sv) 2003-10-02 2005-11-29 Tikomed Ab Bioartificellt implantat innefattande en semipermeabel barriär samt förfarande för reducering av risken för bildning av bindrväv vid implantatet efter implantering genom att barriären förses med en permeabel beläggning av bioaktiv metall
US7935510B2 (en) * 2004-04-30 2011-05-03 Intrexon Corporation Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
JP2007537755A (ja) 2004-05-18 2007-12-27 イントレクソン コーポレイション Ｄｎａクローニングベクタープラスミドのダイナミックなベクター構築のための方法
US9034650B2 (en) 2005-02-02 2015-05-19 Intrexon Corporation Site-specific serine recombinases and methods of their use
US7868159B2 (en) * 2005-06-23 2011-01-11 Baylor College Of Medicine Modulation of negative immune regulators and applications for immunotherapy
CA2625875C (en) 2005-10-21 2013-12-24 Living Cell Products Pty Limited Encapsulation system
MX2010003371A (es) * 2007-09-28 2010-05-05 Intrexon Corp Constructos interruptores genicos terapeuticos y biorreactores para la expresion de moleculas bioterapeuticas y usos de los mismos.
BRPI0818287A2 (pt) * 2007-10-08 2015-11-03 Intrexon Corp células dendríticas manipuladas e usos para o tratamento do câncer.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066613A2 (en) * 2001-02-20 2002-08-29 Rheogene Holdings, Inc Novel ecdysone receptor/invertebrate retinoid x receptor-based inducible gene expression system
JP2005507247A (ja) * 2001-09-26 2005-03-17 レオジーン・ホールディングス，インコーポレーテッド コナジラミエクジソン受容体核酸、ポリペプチド、およびそれらの使用
US20060228776A1 (en) * 2004-10-22 2006-10-12 Neurologix, Inc. PINK-1 promoter

Also Published As

Publication number Publication date
ZA201000983B (en) 2011-04-28
US20160145688A1 (en) 2016-05-26
CN101835908A (zh) 2010-09-15
EP2185730A4 (en) 2010-10-27
US9605316B2 (en) 2017-03-28
EP2185730A1 (en) 2010-05-19
US20130266947A1 (en) 2013-10-10
WO2009025866A1 (en) 2009-02-26
AU2008289461A1 (en) 2009-02-26
US20090098055A1 (en) 2009-04-16
CA2698212A1 (en) 2009-02-26
US9222121B2 (en) 2015-12-29
KR20100049084A (ko) 2010-05-11
MX2010001993A (es) 2010-03-11
US20150056631A1 (en) 2015-02-26
NZ583430A (en) 2012-06-29
US20170145520A1 (en) 2017-05-25

Similar Documents

Publication Publication Date Title
JP2010536373A (ja) 疾患を診断するための方法および組成物
US10314926B2 (en) Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
TWI582108B (zh) 條件性表現蛋白質之載體類
RU2484132C2 (ru) Модифицированные дендритные клетки и их применение в лечении злокачественных опухолей
ES2385598T3 (es) Sistema novedoso de expresión génica inducible basado en el receptor de ecdisona/receptor X retinoide de invertebrado
Chen et al. BCL11A represses HBG transcription in K562 cells
Tung et al. FTO is necessary for the induction of leptin resistance by high-fat feeding
De Martino et al. The glucocorticoid receptor and the orphan nuclear receptor chicken ovalbumin upstream promoter-transcription factor II interact with and mutually affect each other’s transcriptional activities: implications for intermediary metabolism
WO2020081972A1 (en) Myocardial enhancer rna and methods of use
CA2303844A1 (en) Regulators of ucp3 gene expression
WO2004020581A2 (en) Mammalian genes involved in rapamycin resistance and tumorgenesis: rapr7 genes
JP2004344072A (ja) Ｓｍｎ遺伝子のスプライシング調節エレメント
Brogan Structure and function of the glucocorticoid receptor in glucocorticoid resistant human small cell lung cancer
Pontrelli Role of the 5'and 3'untranslated regions in translational control of apolipoprotein B mRNA
Thaiparambil Cardiac-specific and hypertrophy-induced expression of myosin light chain-2v is mediated by the transcription factor, Nishéd
Yin et al. The 130kDa Smooth Muscle Myosin Light Chain Kinase is Transcribed from a CArG

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110824

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130819

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131114

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131204

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20140509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140509